8-K
filed November 3, 2023, 7:59 PM ET
ticker IRMD
CIK 0001325618
earnings
confidence high
sentiment positive
materiality 0.80
Iradimed reports record Q3 revenue $16.5M, raises FY GAAP EPS guidance to $1.34-$1.37
IRADIMED CORP
2023-Q3 EPS reported
$0.99
revenue$48,110,120
- Q3 revenue $16.5M (+23% YoY); GAAP diluted EPS $0.40 vs $0.27 YoY; non-GAAP diluted EPS $0.43 vs $0.29 YoY.
- Operating income $5.9M, up 43% YoY; ninth consecutive quarterly revenue record led by monitoring business up 40% QoQ.
- Q4 2023 guidance: revenue $16.9M-$17.4M; GAAP EPS $0.35-$0.38; non-GAAP EPS $0.38-$0.41.
- Full-year 2023 guidance raised: revenue $65.0M-$65.5M; GAAP EPS $1.34-$1.37 (up from prior); non-GAAP EPS $1.48-$1.51.
- Cash flow from operations $3.5M in Q3 ($9.6M YTD) vs $2.4M ($7.0M YTD) YoY.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 1.0
IRADIMED CORP reported nine months ended September 30, 2023 results: net income $14.0 million, EPS $1.1.
- Period
- nine months ended September 30, 2023
- Net income
- $14.0 million
- EPS
- $1.1
- Result
- reported results
Exact text from the filing
For the nine months ended September 30, 2023, the Company reported revenue of $48.1 million compared to $38.4 million for the same period of 2022. Net income was $12.7 million, or $0.99 per diluted share, compared to $9.2 million, or $0.72 per diluted share for the same period of 2022.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 1.0
IRADIMED CORP reported nine months ended September 30, 2023 results: net income $14.0 million, EPS $1.1.
- Period
- nine months ended September 30, 2023
- Net income
- $14.0 million
- EPS
- $1.1
- Result
- reported results
Exact text from the filing
Non-GAAP net income was $14.0 million, or $1.1 per diluted share, for the nine months ended September 30, 2023, and excludes $1.3 million of stock compensation expense, net of tax expense.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 1.0
IRADIMED CORP reported fourth quarter 2023 results: EPS $0.38 to $0.41. Guidance initiated.
- Period
- fourth quarter 2023
- EPS
- $0.38 to $0.41
- Guidance
- initiated
- Result
- guidance update
Exact text from the filing
For the fourth quarter of 2023, the Company expects to report revenue of $16.9 million to $17.4 million, GAAP diluted earnings per share of $0.35 to $0.38, and non-GAAP diluted earnings per share of $0.38 to $0.41.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 1.0
IRADIMED CORP reported third quarter ended September 30, 2023 results: net income $5.5 million, EPS $0.43.
- Period
- third quarter ended September 30, 2023
- Net income
- $5.5 million
- EPS
- $0.43
- Result
- reported results
Exact text from the filing
For the third quarter ended September 30, 2023, the Company reported over 23% year-over-year revenue growth to $16.5 million compared to $13.4 million for the third quarter of 2022. Net income was $5.1 million, or $0.40 per diluted share, compared to $3.4 million, or $0.27 per diluted share for the third quarter of 2022.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 1.0
IRADIMED CORP reported third quarter ended September 30, 2023 results: net income $5.5 million, EPS $0.43.
- Period
- third quarter ended September 30, 2023
- Net income
- $5.5 million
- EPS
- $0.43
- Result
- reported results
Exact text from the filing
Non-GAAP net income was $5.5 million, or $0.43 per diluted share, for the quarter ended September 30, 2023, and excludes $0.4 million of stock compensation expense, net of tax expense.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 1.0
IRADIMED CORP reported full-year 2023 results: EPS $1.48 to $1.51. Guidance raised.
- Period
- full-year 2023
- EPS
- $1.48 to $1.51
- Guidance
- raised
- Result
- guidance update
Exact text from the filing
For the full-year 2023 financial guidance, the Company now expects to report revenue of $65.0 million to $65.5 million, GAAP diluted earnings per share of $1.34 to $1.37, and non-GAAP diluted earnings per share of $1.48 to $1.51.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.